Mural Oncology Files Definitive Proxy Materials

TL;DR

Mural Oncology filed proxy docs, shareholders need to pay attention.

AI Summary

Mural Oncology plc filed a DEFA14A on October 6, 2025, indicating it is a definitive additional material filing. The company, previously known as Mural Oncology Ltd and Pistachiovale Ltd, is incorporated in L2 with its fiscal year ending December 31st. Its business and mailing address are both located at 10 Earlsfort Terrace, Dublin 2, L2, D02 T380.

Why It Matters

This filing provides important information to shareholders regarding company matters, likely related to upcoming votes or decisions that could impact the company's direction and shareholder value.

Risk Assessment

Risk Level: low — This is a routine proxy filing and does not inherently indicate new risks or significant changes in the company's operations.

Key Players & Entities

• Mural Oncology plc (company) — Registrant
• Mural Oncology Ltd (company) — Former company name
• Pistachiovale Ltd (company) — Former company name
• 10 Earlsfort Terrace, Dublin 2, L2, D02 T380 (company) — Business and mailing address

FAQ

Key Financial Figures

• $2.035 — r (i) will receive a base cash price of $2.035 per share as the Base Price Per Share a
• $0.205 — ditional cash amount per share of up to $0.205 as the Additional Price Per Share, whic
• $36.2 million — the basis of Mural having approximately $36.2 million in Closing Net Cash, as of the Estimate
• $2.24 — hareholders following the Completion is $2.24 per share. Each Mural Option that is

Filing Documents

• d891030ddefa14a.htm (DEFA14A) — 82KB
• 0001193125-25-230979.txt ( ) — 84KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under Rule 14a-12 Mural Oncology plc (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee previously paid with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Commencing October 6, 2025, the following script will be used in discussions with shareholders of Mural Oncology plc by MacKenzie Partners, Inc., Mural Oncology plc's proxy solicitor in connection with the Scheme Meeting and the Extraordinary General Meeting to be held on October 24, 2025. MURAL ONCOLOGY PLC, CALL SCRIPT Introduction: Good (afternoon/evening) this is [caller's name], I am calling from MacKenzie Partners on behalf of Mural Oncology plc regarding [shareholder's name] investment in Mural Oncology plc. MacKenzie Partners is acting as proxy solicitor for the Company's upcoming Scheme Meeting and Extraordinary General Meeting, which are scheduled for October 24, 2025. Is this a convenient time to call? If the shareholder is not available: When would be a good time for us to reach him/her? We will call back then. Thank you, good-bye. If shareholder answers the phone: Thank you for taking my call; I'm calling to confirm that you've received the proxy statement and voting instruction forms related to the Scheme Meeting and Extraordinary General Meeting and to inquire if you have any questions. If shareholder has not yet received the proxy materials: We will call back in [state number of days], hopefully you will have received the materials at that time. Thank you for taking the time to speak today. Goodbye. If shareholder has questions: [Caller will refer to the Q&A section (please see the end of this document) from the proxy statement to answer any question(s) posed by the shareholder. If the shareholder has a question that is not covered by the Q&A, the caller will inform the shareholder they cannot offer a response but will pass along the question to the Company and, if appropriate, the Company will revert.] If no questions or the caller has answered all questions posed by the shareholder: Thank you. Do you need any assistance in voting your shares? If so, I can accept your voting instructions over the phone. If the shareholder requests the caller process the shareholder's vote instructions: I will now record our call if I have your permission to do so. [caller will pause for shareholder's permission to record the call] If the shareholder agrees to have the call recorded: I will now read the proposals from the voting instruction form for each meeting that you are requested to vote upon. I will pause after each proposal for you to provide me your voting response. [caller reads each proposal for each of the two meetings, pausing to allow the shareholder to provide their response] Thank you for taking the time to speak with me today. Have a good [day/evening]. If the shareholder does not agree to have the call recorded: Thank you for taking the time to speak with me today. On behalf of Mural Oncology, you are urged to submit your vote instructions ahead of the deadline. Have a good (day/evening). Questions & Answers Q: Why did I receive the proxy statement? A: You, as a Mural Shareholder, received the proxy statement because Mural, XOMA Royalty Corporation and XRA 5 Corp entered into the Transaction Agreement on August 20, 2025, pursuant to which, on the terms and subject to the conditions set forth therein, XRA 5 Corp has agreed to acquire the entire issued and to be issued share capital of Mural, which Acquisition shall be implemented by means of the Scheme to be undertaken by Mural under Chapter 1 of Part 9 of the Companies Act 2014. The Mural Board has convened the Scheme Meeting to be held at Ten Earlsfort Terrace, Dublin 2, D02 T380, Ireland at 10:30 a.m. Irish local time on October 24, 2025 in order to obtain shareholder approval of the Scheme of Arrangement. At 10:45 a.m. Irish local time on October 24, 2025, or, if the Scheme Meeting has not concluded by 10:45 a.m. Irish local time, as soon as possible after the conclusion of the Scheme Meeting (or any adjournment thereof), Mural will hold the EGM in order to obtain shareholder approval of the Required EGM Resolutions and the EGM Adjournment Resolution. It will not be possible to complete the Acquisition unless the requisite Mural Shareholder approval

View Full Filing

View this DEFA14A filing on SEC EDGAR